Pfizer looking to sell option for Lpath's iSONEP

Lpath Inc. (NASDAQ:LPTN) said Pfizer Inc. (NYSE:PFE) plans to sell its exclusive option to license worldwide rights to Lpath's iSONEP, which is in the Phase IIa Nexus trial to treat wet age-related macular degeneration (AMD). Lpath said it made an offer to reaquire the option from the pharma. Data from the Nexus trial are expected in 3Q14. Lpath granted Pfizer the option for iSONEP -- an ocular formulation of humanized sphingomab, a mAb against the sphingosine 1-phosphate (S1P) receptor -- in 2010. Earlier this year, Pfizer said it is prioritizing R&D efforts into immunology, inflammation, cancer, cardiovascular, metabolic, neurology and vaccine indications (see BioCentury Extra, July 29). ...